Karyopharm (KPTI) appointed Lori Macomber as EVP, CCFO and Treasurer, effective January 3. Macomber has over 20 years of experience in financial strategies for life science companies. Most recently, she served as CFO at Legend Biotech, a publicly traded, commercial-stage biopharmaceutical company. Previously, Macomber held leadership roles of increasing responsibility with Ametek PDS, Cello Health, Eli Lilly and Pfizer. In connection with Macomber’s appointment as CFO, effective as of January 31, the company granted Macomber inducement awards consisting of a non-statutory stock option to purchase 650K shares of Karyopharm’s common stock and 160K restricted stock units. The Inducement Option vests over four years. The Inducement RSU Award will vest over three years.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm Engages with FDA on Cancer Trial Plans
- Karyopharm reports inducement grants under Nasdaq listing rule
- Karyopharm Therapeutics Appoints New Chief Accounting Officer
- Karyopharm appoints Kristin Abate as Chief Accounting Officer
- Karyopharm price target raised to $5 from $4 at Piper Sandler
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
